Mielóma multiplex: vizsgálatok itt: Argentína

In Argentína 10 Also abroad 704

10 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.

2. fázisTaking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Buenos Aires, Córdoba, Pilar
Életkor
18 év and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
3. fázisTaking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Buenos Aires, Chivilcoy, Córdoba, Rosario, S3000epv, Viedma
Életkor
18 év and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
ABB, Buenos Aires
Életkor
18 év and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
3. fázisTaking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Córdoba, Rosario
Életkor
18 év and over
People
1060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
3. fázisTaking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Buenos Aires, Córdoba, Rosario
Életkor
18 év and over
People
1594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
3. fázisTaking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, La Plata, Presidente Derqui, Rosario
Életkor
18 év and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
3. fázisTaking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Ciudad Autónoma de Buenos Aires, Ciudad de Buenos Aires, La Plata, Pilar
Életkor
18 év and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
1/2. fázisTaking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Capital Federal, Ciudadela, Rosario, San Juan Bautista, Viedma
Életkor
18 év and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
3. fázisTaking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Capital Federal, Ciudad Autonoma de Buenos Aire, Córdoba, Rosario, Viedma
Életkor
18 év and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Córdoba
Életkor
18 év and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757